Hemogenyx Pharmaceuticals Expands Pediatric R/R AML Trial for HG-CT-1 CAR-T Therapy

Hemogenyx Pharmaceuticals plc announced a protocol amendment to include pediatric patients with relapsed/refractory acute myeloid leukemia (R/R AML) i...
Home/KnloSights/Clinical Trial Updates/Hemogenyx Pharmaceuticals Expands Pediatric R/R AML Trial for HG-CT-1 CAR-T Therapy